[go: up one dir, main page]

ZA909893B - Iontophoretic delivery method - Google Patents

Iontophoretic delivery method

Info

Publication number
ZA909893B
ZA909893B ZA909893A ZA909893A ZA909893B ZA 909893 B ZA909893 B ZA 909893B ZA 909893 A ZA909893 A ZA 909893A ZA 909893 A ZA909893 A ZA 909893A ZA 909893 B ZA909893 B ZA 909893B
Authority
ZA
South Africa
Prior art keywords
delivery method
iontophoretic delivery
iontophoretic
delivery
Prior art date
Application number
ZA909893A
Other languages
English (en)
Inventor
Ronald P Haak
P Haak Ronald
J Richard Gyory
Richard Gyory J
Jane Yieh
Yieh Jane
Original Assignee
Alza Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp filed Critical Alza Corp
Publication of ZA909893B publication Critical patent/ZA909893B/xx

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61NELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00Electrotherapy; Circuits therefor
    • A61N1/02Details
    • A61N1/04Electrodes
    • A61N1/0404Electrodes for external use
    • A61N1/0408Use-related aspects
    • A61N1/0428Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Electrotherapy Devices (AREA)
  • Medicinal Preparation (AREA)
ZA909893A 1989-12-14 1990-12-10 Iontophoretic delivery method ZA909893B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US07/452,136 US5167616A (en) 1989-12-14 1989-12-14 Iontophoretic delivery method

Publications (1)

Publication Number Publication Date
ZA909893B true ZA909893B (en) 1991-09-25

Family

ID=23795191

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA909893A ZA909893B (en) 1989-12-14 1990-12-10 Iontophoretic delivery method

Country Status (7)

Country Link
US (1) US5167616A (xx)
AU (1) AU6972591A (xx)
CA (1) CA2031873A1 (xx)
IE (1) IE904437A1 (xx)
PT (1) PT96151A (xx)
WO (1) WO1991008795A2 (xx)
ZA (1) ZA909893B (xx)

Families Citing this family (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69029399T2 (de) * 1989-10-23 1997-04-17 Theratech Inc Vorrichtung für Iontophorese unter Verwendung einer Durchfluss-kontrollierenden Membran
DE69127205T2 (de) * 1990-11-28 1998-03-05 Sano Corp., Pembroke Pines, Fla. Vorrichtung zum behandeln von tabakabhängigkeit
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5464387A (en) * 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US5246417A (en) * 1991-12-11 1993-09-21 Alza Corporation Indicator for iontophoresis system
EP0552879B1 (en) * 1992-01-21 1998-08-19 Macrochem Corporation Improved iontophoretic administration of drugs
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5508262A (en) * 1993-12-15 1996-04-16 University Of South Florida Interleukin-1 receptor antagonist decreases severity of acute pancreatitis
US5700481A (en) * 1995-03-17 1997-12-23 Takeda Chemical Industries, Ltd. Transdermal drug delivery process
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
US5855867A (en) * 1995-03-29 1999-01-05 The Curators Of The University Of Missouri Hydroxymethyl phosphine compounds for use as diagnostic and therapeutic pharmaceuticals and method of making same
ZA964320B (en) * 1995-06-05 1997-01-13 Alza Corp Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6881208B1 (en) * 1995-06-05 2005-04-19 Joseph B. Phipps Method and device for transdermal electrotransport delivery of fentanyl and sufentanil
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
US5767084A (en) * 1995-10-06 1998-06-16 The Curators Of The University Of Missouri Method of treatment for cystic fibrosis and peptides for same
CA2235036A1 (en) 1995-11-08 1997-05-15 University Of South Florida Guinea pig model for leiomyomas and atherosclerosis
US5779661A (en) * 1995-12-11 1998-07-14 Physion, S.R.L. Method of treating dysfunctional bladder syndromes by electromotive drug administration
AU3404097A (en) * 1996-06-19 1998-01-07 Becton Dickinson & Company Iontophoretic delivery of cell adhesion inhibitors
US5906976A (en) * 1996-10-22 1999-05-25 Ramot-University Authority For Applied Research And Industrial Development, Ltd. Method and composition for treating neuronal degeneration
US5976547A (en) * 1997-04-22 1999-11-02 Niblick Pharmaceuticals, Inc. Analgesic and antiphlogistic compositions and therapeutic wrap for topical delivery
ATE373957T1 (de) 1997-10-09 2007-10-15 Univ Emory Verfahren und vorrichtung zur transdermalen verabreichung von lithium
JP2001522815A (ja) * 1997-11-12 2001-11-20 アルザ コーポレイション ポリペプチド類の自己会合を減少させる方法
US6489306B2 (en) 1998-02-23 2002-12-03 University Of South Florida Method of intranasal gene transfer for protection against respiratory infection
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6338834B1 (en) 1998-04-30 2002-01-15 The Curators Of The University Of Missouri Melanotropin analogs for potential radiopharmaceuticals for diagnosis and treatment of melanoma
US6344443B1 (en) 1998-07-08 2002-02-05 University Of South Florida Peptide antagonists of tumor necrosis factor alpha
AU4994899A (en) 1998-07-13 2000-02-01 University Of South Florida Modulation of the phospholipase a2 pathway as a therapeutic
WO2000006696A2 (en) 1998-07-30 2000-02-10 University Of South Florida Method for the modulation of function of transcription factors
US6780397B2 (en) 1998-09-01 2004-08-24 Curators Of The University Of Missouri Biomolecule conjugation strategy using novel water-soluble phosphine-based chelating agents
US6638974B1 (en) 1999-04-09 2003-10-28 University Of South Florida Ascorbyl esters for the treatment of cancer
US6787318B1 (en) * 1999-06-01 2004-09-07 Roskamp Research Institute, Llc Assay for evaluating the therapeutic effectiveness of agents in reducing Alzheimer's disease pathology
JP2003532622A (ja) * 1999-06-14 2003-11-05 ヘンリー フォード ヘルス システム 神経発生を誘導する一酸化窒素ドナー
US7655423B2 (en) * 1999-06-14 2010-02-02 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US7135498B1 (en) 1999-06-14 2006-11-14 Henry Ford Health System Nitric oxide donors for inducing neurogenesis
US6998232B1 (en) 1999-09-27 2006-02-14 Quark Biotech, Inc. Methods of diagnosing bladder cancer
AU4710401A (en) 1999-12-02 2001-06-18 University Of South Florida Method and composition for treatment of ischemic neuronal reperfusion injury
WO2002003921A2 (en) * 2000-07-11 2002-01-17 University Of South Florida Bax fragment induced tumor cell death
US6803060B2 (en) 2000-09-07 2004-10-12 Joe Reyes Composition to boost libido
EP1337149A4 (en) * 2000-10-27 2005-10-12 Irx Therapeutics Inc VACCINE IMMUNOTHERAPY FOR IMMUNE-PATIENT PATIENTS
US7182942B2 (en) * 2000-10-27 2007-02-27 Irx Therapeutics, Inc. Vaccine immunotherapy for immune suppressed patients
US20070154399A1 (en) * 2000-10-27 2007-07-05 Hadden John W Immunotherapy for immune suppressed patients
US20070025958A1 (en) * 2000-10-27 2007-02-01 Hadden John W Vaccine immunotherapy
US20060194242A1 (en) * 2000-10-27 2006-08-31 Hadden John W Immunotherapy for immune suppressed patients
US20070031372A1 (en) * 2004-08-05 2007-02-08 Hadden John W Vaccine immunotherapy for immune suppressed patients
US6770622B2 (en) 2001-06-08 2004-08-03 Gary A. Jarvis N-terminally truncated galectin-3 for use in treating cancer
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
EP1446159A4 (en) * 2001-10-26 2005-06-01 Irx Therapeutics Inc IMMUNOTHERAPY FOR REVERSING AN IMMUNE UPPRESSION
US7458982B2 (en) * 2002-10-04 2008-12-02 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
AU2003284968A1 (en) * 2002-10-25 2004-05-13 University Of South Florida Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease
US7220778B2 (en) * 2003-04-15 2007-05-22 The General Hospital Corporation Methods and devices for epithelial protection during photodynamic therapy
EP1662879A4 (en) * 2003-08-29 2009-03-11 Univ New York INDIRECT DELIVERY OF GROWTH FACTORS IN THE CENTRAL NERVOUS SYSTEM
ES2389805T3 (es) * 2003-09-12 2012-10-31 University Of Colorado Glutamina para su uso en el tratamiento de una lesión
WO2005059100A2 (en) * 2003-12-12 2005-06-30 New York University Methods and compositions relating to cystatin c
JP2007528369A (ja) * 2003-12-30 2007-10-11 シンドロメクス・リミテッド 3,3,14,14−テトラメチルヘキサデカン−1,16−ジオイック酸の投与法
ATE491715T1 (de) 2004-01-30 2011-01-15 Quark Pharmaceuticals Inc Oligoribonukleotide und verfahren zu deren anwendung bei der behandlung von fibrotischen leiden und anderen krankheiten
US7666914B2 (en) * 2004-06-03 2010-02-23 Richlin David M Topical preparation and method for transdermal delivery and localization of therapeutic agents
KR101094617B1 (ko) 2004-08-16 2011-12-15 사일런스 테라퓨틱스 아게 알티피801 억제제의 치료적 용도
KR101409241B1 (ko) 2004-09-28 2014-06-24 쿠아크 파마수티칼스 인코퍼레이티드 탈모증, 급성신부전증 및 다른 질환의 치료를 위한 올리고리보뉴클레오티드 및 그것의 사용방법
US8386030B2 (en) 2005-08-08 2013-02-26 Tti Ellebeau, Inc. Iontophoresis device
US8295922B2 (en) 2005-08-08 2012-10-23 Tti Ellebeau, Inc. Iontophoresis device
US20070088331A1 (en) * 2005-08-18 2007-04-19 Transcutaneous Technologies Inc. Method and apparatus for managing active agent usage, and active agent injecting device
BRPI0616165A2 (pt) 2005-09-15 2011-06-07 Tti Ellebeau Inc dispositivo de iontoforese do tipo de haste
US20070083185A1 (en) * 2005-09-30 2007-04-12 Darrick Carter Iontophoretic device and method of delivery of active agents to biological interface
US8541177B2 (en) 2006-01-13 2013-09-24 A Chan Holding B.V. Treatment and diagnosis of abnormal bone density with an inhibitor of the glypican-sclerostin interaction
DOP2007000015A (es) 2006-01-20 2007-08-31 Quark Biotech Inc Usos terapéuticos de inhibidores de rtp801
US20080077076A1 (en) * 2006-08-29 2008-03-27 Transcutaneous Technologies Inc. Iontophoresis device and method for operation with a usb (universal serial bus) power source
US20080260678A1 (en) * 2006-10-10 2008-10-23 University Of Colorado Molecular band-aid
JP2010507387A (ja) 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のsiRNAおよびその使用方法
KR20090106492A (ko) * 2006-12-01 2009-10-09 티티아이 엘뷰 가부시키가이샤 경피성 전달 장치와 같은 장치에 전력을 제공하거나 제어하기 위한 시스템, 장치, 및 방법
US8197844B2 (en) 2007-06-08 2012-06-12 Activatek, Inc. Active electrode for transdermal medicament administration
US8729121B2 (en) 2007-06-25 2014-05-20 Adhezion Biomedical, Llc Curing accelerator and method of making
WO2010008822A2 (en) 2008-06-23 2010-01-21 Adhezion Biomedical, Llc Cyanoacrylate tissue adhesives with desirable permeability and tensile strength
EP2164418B1 (en) * 2007-06-27 2014-01-08 The General Hospital Corporation Apparatus for optical inhibition of photodynamic therapy
DK2170403T3 (da) 2007-06-27 2014-06-16 Quark Pharmaceuticals Inc Sammensætninger og fremgangsmåder til hæmning af ekspressionen af proapoptotiske gener
US8614309B2 (en) 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
EP2211727B1 (en) 2007-11-14 2014-03-12 Adhezion Biomedical, LLC Cyanoacrylate tissue adhesives
US8862223B2 (en) 2008-01-18 2014-10-14 Activatek, Inc. Active transdermal medicament patch and circuit board for same
EP2106791A1 (en) 2008-03-31 2009-10-07 Biotempt B.V. Glutamine or glutamine-containing dipeptide in a specific dosage for the treatment of inflammation
US8198344B2 (en) 2008-06-20 2012-06-12 Adhezion Biomedical, Llc Method of preparing adhesive compositions for medical use: single additive as both the thickening agent and the accelerator
US8293838B2 (en) 2008-06-20 2012-10-23 Adhezion Biomedical, Llc Stable and sterile tissue adhesive composition with a controlled high viscosity
US8652510B2 (en) 2008-10-31 2014-02-18 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US9254133B2 (en) 2008-10-31 2016-02-09 Adhezion Biomedical, Llc Sterilized liquid compositions of cyanoacrylate monomer mixtures
US8609128B2 (en) 2008-10-31 2013-12-17 Adhezion Biomedical, Llc Cyanoacrylate-based liquid microbial sealant drape
US20110288155A1 (en) 2008-12-18 2011-11-24 Elena Feinstein Sirna compounds and methods of use thereof
ES2628228T3 (es) 2009-03-26 2017-08-02 Henry Ford Health System Timosina beta 4 para su utilización en el tratamiento de una lesión neural
US8637482B2 (en) 2009-06-08 2014-01-28 Quark Pharmaceuticals, Inc. Methods for treating chronic kidney disease
EP2504435B1 (en) 2009-11-26 2019-11-13 Quark Pharmaceuticals, Inc. Sirna compounds comprising terminal substitutions
TWI611021B (zh) 2009-12-09 2018-01-11 日東電工股份有限公司 Hsp47表現之調節
EP2862929B1 (en) 2009-12-09 2017-09-06 Quark Pharmaceuticals, Inc. Compositions and methods for treating diseases, disorders or injury of the CNS
WO2011084193A1 (en) 2010-01-07 2011-07-14 Quark Pharmaceuticals, Inc. Oligonucleotide compounds comprising non-nucleotide overhangs
MX2012009678A (es) 2010-02-22 2013-06-03 Health Enhancement Products Inc Agentes y mecanismos para tratar la hipercolesterolemia.
US9309019B2 (en) 2010-05-21 2016-04-12 Adhezion Biomedical, Llc Low dose gamma sterilization of liquid adhesives
NZ604094A (en) 2010-06-24 2014-11-28 Quark Pharmaceuticals Inc Double stranded rna compounds to rhoa and use thereof
US20140134231A1 (en) 2010-10-11 2014-05-15 Sanford-Burnham Medical Research Institute Mir-211 expression and related pathways in human melanoma
AU2011338682B2 (en) 2010-12-06 2017-04-27 Quark Pharmaceuticals, Inc. Double stranded oligonucleotide compounds comprising threose modifications
CN103492572A (zh) 2011-03-03 2014-01-01 夸克医药公司 用于治疗肺疾病和损伤的组合物和方法
US9796979B2 (en) 2011-03-03 2017-10-24 Quark Pharmaceuticals Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2012118911A1 (en) 2011-03-03 2012-09-07 Quark Pharmaceuticals, Inc. Oligonucleotide modulators of the toll-like receptor pathway
WO2013003697A1 (en) 2011-06-30 2013-01-03 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
JP2015509085A (ja) 2012-01-01 2015-03-26 キュービーアイ エンタープライゼズ リミテッドQbi Enterprises Ltd. 治療剤および診断剤の選択的送達のためのendo180を標的とする粒子
CA2858630A1 (en) 2012-01-12 2013-07-18 Quark Pharmaceuticals, Inc. Combination therapy for treating hearing and balance disorders
WO2013173923A1 (en) 2012-05-25 2013-11-28 Diamedica, Inc. Formulations of human tissue kallikrein-1 for parenteral delivery and related methods
HUE032613T2 (en) 2012-06-04 2017-10-30 Diamedica Therapeutics Inc Human tissue kallikrein 1 is glycosylated isoforms
CN104619727B (zh) 2012-06-25 2019-04-05 布里格姆及妇女医院股份有限公司 靶向治疗
WO2014043291A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded nucleic acid compounds
DK2895607T3 (da) 2012-09-12 2021-05-25 Quark Pharmaceuticals Inc Dobbeltstrengede oligonukleotidmolekyler til ddit4 og fremgangsmåder til anvendelse deraf
WO2014043292A1 (en) 2012-09-12 2014-03-20 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
CA2893427C (en) 2012-12-24 2023-01-10 Neurogastrx, Inc. Methods for treating gi tract disorders
DK2968470T3 (da) 2013-03-12 2021-02-01 Massachusetts Gen Hospital Modificeret müllersk inhiberende substans (mis)-proteiner og anvendelser deraf til behandlingen af sygdomme
US10232028B2 (en) 2013-06-13 2019-03-19 Zivo Bioscience, Inc. Compounds and methods for affecting cytokines
WO2015020960A1 (en) 2013-08-09 2015-02-12 Novartis Ag Novel lncrna polynucleotides
DK3079712T3 (da) 2013-12-11 2022-04-25 Massachusetts Gen Hospital Anvendelse af müllersk inhiberende substans- (mis) proteiner til kontraception og ovariereservebevarelse
US9421297B2 (en) 2014-04-02 2016-08-23 Adhezion Biomedical, Llc Sterilized compositions of cyanoacrylate monomers and naphthoquinone 2,3-oxides
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
CN104353183B (zh) * 2014-10-31 2016-12-07 厦门微科格瑞生物科技有限公司 电解液位置固定的可佩戴智能药物导入结构
CA3011687A1 (en) 2015-02-16 2016-08-25 Zivo Bioscience, Inc. Methods of modulating immune and inflammatory responses via administration of an algal biomass
EP3416501A4 (en) 2016-02-16 2019-11-20 Zivo Bioscience, Inc. NUTRITIONAL SUPPLEMENT FOR ANIMALS BY ADMINISTERING A FOOD SUPPLEMENT FROM ALGAE
WO2018165551A1 (en) 2017-03-09 2018-09-13 Diamedica Inc. Dosage forms of tissue kallikrein 1
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
EP3922720A1 (en) 2020-06-09 2021-12-15 Universidad de Murcia Therapy to prevent adverse cardiac remodeling following an acute myocardial infarction
US20220265582A1 (en) 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3991755A (en) * 1973-07-27 1976-11-16 Medicon, Inc. Iontophoresis apparatus for applying local anesthetics
US4767401A (en) * 1975-04-22 1988-08-30 Maurice Seiderman Iontophoretic administration of ionizable or polar medicaments to a mammalian body
US4141359A (en) * 1976-08-16 1979-02-27 University Of Utah Epidermal iontophoresis device
US4250878A (en) * 1978-11-22 1981-02-17 Motion Control, Inc. Non-invasive chemical species delivery apparatus and method
CA1153427A (en) * 1978-12-11 1983-09-06 Patrick T. Cahalan Tape electrode
WO1981000964A1 (en) * 1979-10-10 1981-04-16 Cyclotech Med Ind Pain blocking bandage
US4382529A (en) * 1980-12-15 1983-05-10 Drdlik Frank J Sanitary dispensing closure
JPS5810066A (ja) * 1981-07-10 1983-01-20 株式会社アドバンス イオントフオレ−ゼ用プラスタ−構造体
US4919648A (en) * 1983-08-18 1990-04-24 Drug Delivery Systems Inc. High tack drug patch
CA1262564A (en) * 1983-09-01 1989-10-31 Minoru Sasaki Iontophoresis device
US4725439A (en) * 1984-06-29 1988-02-16 Alza Corporation Transdermal drug delivery device
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4809707A (en) * 1985-04-12 1989-03-07 Kvm Engineering, Inc. Electrode for non-invasive allergy testing
US4722726A (en) * 1986-02-12 1988-02-02 Key Pharmaceuticals, Inc. Method and apparatus for iontophoretic drug delivery
US4786277A (en) * 1986-11-21 1988-11-22 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation
FR2607708B3 (fr) * 1986-12-05 1989-02-24 Bontemps Raymond Dispositif destine au transfert sous-cutane de substances medicinales
US4878892A (en) * 1987-02-10 1989-11-07 Drug Delivery Systems Inc. Electrolytic transdermal delivery of polypeptides
US4940456A (en) * 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US4931046A (en) * 1987-05-15 1990-06-05 Newman Martin H Iontophoresis drug delivery system
US4942883A (en) * 1987-09-29 1990-07-24 Newman Martin H Drug delivery device

Also Published As

Publication number Publication date
PT96151A (pt) 1991-09-30
WO1991008795A3 (en) 1991-07-25
AU6972591A (en) 1991-07-18
IE904437A1 (en) 1991-06-19
WO1991008795A2 (en) 1991-06-27
CA2031873A1 (en) 1991-06-15
US5167616A (en) 1992-12-01

Similar Documents

Publication Publication Date Title
ZA909893B (en) Iontophoretic delivery method
GB8910880D0 (en) Sequencing method
GB2233996B (en) Well treatment method
GB8814705D0 (en) Method
EP0411146A4 (en) Interface for iontophoresis
GB8913090D0 (en) Method
GB2160427B (en) Electrotherapeutic apparatus
EP0326421A3 (en) An electroanalytical method
DE3565667D1 (en) Delivery apparatus
GB8822145D0 (en) Method
GB2160426B (en) Electrotherapeutic apparatus
GB8827847D0 (en) Method
GB8829942D0 (en) Method
GB8722188D0 (en) Dispensing method
GB8720505D0 (en) Iontophoretic apparatus
GB8526529D0 (en) Delivery apparatus
GB8912936D0 (en) Time controls
GB8914748D0 (en) New method
GB8810354D0 (en) Method
GB9200682D0 (en) Noncorruptible read-writer method
GB8927300D0 (en) Therapeutic method
GB8909493D0 (en) Stimulation
GB8912239D0 (en) Treating method
GB9024592D0 (en) Fencing
GB8928436D0 (en) New therapeutic method